Saturday, October 18th , 2025 • Toronto, ON
The 2025 Rising Stars in Malignant Hematology Conference will serve a foundational role in helping early-in-practice hematologists gain meaningful insight into patient and disease management for hematologic malignancies. This event is geared towards the early-in-practice clinician and will include didactic lectures, complex case discussions, and panel Q&A sessions.
Only 40 spots, including limited travel grants, are available for this one-of-a-kind conference and we encourage you to register early.
If you are able to join us, kindly RSVP by registering to the conference using the link below. Registrations will close on August 31st, 2025, or when the conference reaches capacity. As space is limited, we encourage you to RSVP at your earliest convenience if you plan to attend.
The 2025 Rising Stars in Malignant Hematology Conference will serve a foundational role in helping early-in-practice hematologists gain meaningful insight into patient and disease management for hematologic malignancies.
9:00 - 9:15AM
Welcome & Opening Remarks
Alissa Visram
9:15 AM–9:45 AM
Bispecific antibody therapy practical management in 2025
Richard Leblanc
9:45 AM–10:15 AM
CAR T-cell therapy long-term toxicity management in 2025
Christine Chen
10:15 AM–10:45 AM
Sequencing in rrMM in 2025
Irwindeep Sandhu
10:45 AM–11:00 AM
Networking Break
ALL
11:00 AM–11:30 AM
Approach to Hodgkin’s lymphoma in 2025
Mary Margaret Keating
11:30 AM–12:15 PM
Panel Discussion
Full Faculty
12:15 - 1:30PM
LUNCH
ALL
1:30 PM- 2:00 PM
Updates on the management of MPN in 2025
Vikas Gupta
2:00 PM- 2:30 PM
CLL management in 2025 (front-line vs relapse)
Carolyn Owen
2:30 PM- 2:45 PM
Networking Break
ALL
2:45 PM- 3:15 PM
Non-intensive AML therapy: frontline and first relapse
Karen Yee
3:15 PM- 3:45 PM
Relapsed aggressive B-cell lymphoma: A 2025 overview
Michael Chu
3:45 PM- 4:00 PM
Closing Remarks & Adjournment
Peter Anglin
Canadian Hematology Today provides a forum for the clinical community to share real-world experience and the latest best practices in the treatment and management of hematologic disease.
The journal is published thrice yearly in English and French and is circulated to over 1,100 hematology clinicians and researchers across Canada. It features peer-reviewed articles that present robust clinical perspectives and practical insights into disease management.
Founded in 2009, Catalytic Health is one of Canada’s largest medical education agencies and reaches over 50,000 Canadian clinicians a year with its educational programs, services and platforms. Catalytic Health is also the largest independent medical publisher in Canada, one of the largest scientific conference providers, and a leader in innovative events and services for the Life Sciences industry. Learn more about Catalytic Health.
© 2025 All Rights Reserved.
Dr. Peter Anglin’s clinical focus remains in haematologic and lymphoid malignancies. He is currently Physician Lead for the Stronach Regional Cancer Centre in Newmarket, Ontario. He has also developed an interest in health systems delivery, process redesign in the ambulatory setting, and optimizing drug access for oncology patients. He continues to serve in an advisory capacity to a number of pharmaceutical and health-related organizations. He remains the medical director of CarePath, a cancer navigation and support service supporting Cancer Care Ontario and Ontario cancer patients.